The Federal Trade Commission has not sued over any healthcare provider mergers since President Donald Trump's return to the White House. Attorneys at the American Health Law Association annual meeting say that's not a signal that the agency is backing off.
Attorneys that helped guide this year’s string of biotech IPOs expect the fast pace of public offerings to continue.
Medical technology provider Novanta Inc., advised by Ropes & Gray LLP and King & Spalding LLP, on Tuesday announced plans to acquire medical device maker Riverpoint Medical, led by Goodwin Procter LLP, from private equity shop Arlington Capital Partners in a deal worth up to $1.45 billion.
Previous
Next
The Federal Trade Commission has not sued over any healthcare provider mergers since President Donald Trump's return to the White House. Attorneys at the American Health Law Association annual meeting say that's not a signal that the agency is backing off.
Attorneys that helped guide this year’s string of biotech IPOs expect the fast pace of public offerings to continue.
Medical technology provider Novanta Inc., advised by Ropes & Gray LLP and King & Spalding LLP, on Tuesday announced plans to acquire medical device maker Riverpoint Medical, led by Goodwin Procter LLP, from private equity shop Arlington Capital Partners in a deal worth up to $1.45 billion.
-
July 02, 2026
This U.S. Supreme Court term featured high-stakes oral arguments on issues including presidential power, immigration and voting regulations. Here's a look at the law firms that argued the most cases and how they fared.
-
July 02, 2026
The sharpest dissents this term often involved the president, and pitted conservative and liberal justices against each other on core constitutional issues and questions about the limits to executive power, with nearly a quarter of cases being decided squarely along ideological lines.
-
July 02, 2026
The Supreme Court's conservative supermajority and President Donald Trump largely aligned this year on issues of executive power, resulting in a series of decisions that significantly expanded presidential authority.
-
July 02, 2026
Chubb, Liberty Mutual and Lloyd's of London units and other insurers urged a Pennsylvania federal court to find that they don't owe any additional coverage to bankrupt pharmaceutical company Endo International for the remainder of third-party payor opioid lawsuits filed against Endo during its 2017-2018 policy period.
-
July 02, 2026
Biotechnology firm United Therapeutics Corp. on Thursday revealed that it has agreed to buy a preclinical-stage biotech company focused on thymic cell therapies in a deal worth up to $300 million.
-
July 02, 2026
The U.S. Supreme Court's stark ideological divisions were on full display this term, particularly as it issued long-awaited rulings in the last few days of June. Here, Law360 dives into the numbers behind this court term.
-
July 01, 2026
French drugmaker Ipsen said Wednesday it has agreed to acquire Swiss biotechnology company Memo Therapeutics AG in a deal that could be worth more than €700 million ($796.6 million), expanding its pipeline of treatments for rare diseases.
-
June 30, 2026
It was deal after deal this past week, as Big Pharma continued to scoop up companies.
-
June 30, 2026
For attorneys defending healthcare clients hit with grand jury subpoenas and other enforcement actions investigating potential cases of fraud, cooperation with federal prosecutors is key.
-
June 30, 2026
A Massachusetts federal judge has permanently dismissed an investor suit alleging Zenas BioPharma hid how quickly it was spending money before its 2024 initial public offering, saying the company warned investors before the IPO that its drug-development costs were high and rising, and therefore did not have to provide a quarter-by-quarter spending breakdown.
-
June 30, 2026
Two former hospital workers urged a Colorado federal court to keep alive their proposed class and collective action alleging University of Colorado Health shorted hourly employees through a time-rounding policy and denied them required meal and rest breaks, saying their claims are sufficiently detailed to proceed.
-
June 29, 2026
A New York federal judge trimmed proposed class action claims by providers alleging Sanofi-Aventis and other drugmakers colluded to deny them discounts on insulin products under the 340B program, allowing most of their state-law antitrust claims to survive but dismissing their unjust enrichment claims.
-
June 29, 2026
A subsidiary of Rock Creek Advisors LLC created to administer the liquidation of an asthma drug developer to pay creditors notified Delaware's chancery court that the company turned to a wind-down after clinical trials came to a halt.
-
June 26, 2026
A former chief executive officer of Washington-based Community Clinic Network has pled guilty to wire fraud in Washington federal court, admitting he drained almost $24.4 million from the healthcare company's coffers, most of which he lost in a series of poor investment decisions.
-
June 26, 2026
In this week's Taxation With Representation, Germany's Merck KGaA acquires life sciences tools supplier Bio-Techne Corp., drugmaker AbbVie buys clinical-stage biotechnology company Apogee Therapeutics, and building materials supplier CRH acquires infrastructure products maker Arcosa Inc.
-
June 25, 2026
The Fourth Circuit on Thursday declined to reinstate a medical supply company's contract dispute against a U.K. corporation over COVID-19 test kits, after finding that the lack of a U.S. citizen on the supply company's side destroys the court's diversity jurisdiction to hear the case.
-
June 24, 2026
Two brothers convicted in a $1.4 billion scheme to bill insurers inflated rates for drug tests told the Eleventh Circuit on Wednesday that there was insufficient evidence to support their convictions and that they should have been allowed an evidentiary hearing after potential juror misconduct emerged following the trial.
-
June 22, 2026
Cassava Sciences investors have asked a Texas federal judge to preliminarily approve a $31 million settlement that ends their claims the pharmaceutical company inflated its stock prices with misleading information about its Alzheimer's drug research, a deal that could be upended if the court's class certification order is reversed on appeal.
-
June 22, 2026
The Federal Trade Commission is allowing Aurobindo Pharma Ltd. to move ahead with its planned $250 million acquisition of Lannett Co. Inc., after the pharmaceutical company agreed to unload four generic drug products to prevent potential overlaps.
-
June 22, 2026
A Texas bankruptcy judge blocked a lawsuit in California federal court alleging Jackson Walker LLP and executives at Sorrento Therapeutics and M3 Partners conspired to forum shop in Texas so the drug developer could seek Chapter 11 protection in an "ethically compromised" bankruptcy court, ruling the suit's claims are barred by Sorrento's bankruptcy plan.
-
June 18, 2026
Venture-backed Kardigan Inc., a biotechnology firm developing therapies for cardiovascular diseases, hit the public markets on Thursday after raising $400 million in its initial public offering.
-
June 16, 2026
Eli Lilly has agreed to drop a lawsuit accusing two Washington clinics of ripping off its trademarks for the weight loss drugs Mounjaro and Zepbound, according to a voluntary dismissal motion filed in federal court on Monday, almost two weeks after a judge rejected a resolution proposed by the parties.
-
June 12, 2026
In this week's Taxation With Representation, SpaceX prices a $75 billion initial public offering at its designated price range, Apollo Global Management leads a capital commitment for a Broadcom initiative to build artificial intelligence infrastructure for companies including Anthropic, and pharma giant GSK acquires cancer therapy specialist Nuvalent.
-
June 11, 2026
Precision oncology startup Ignite Proteomics LLC will merge with special purpose acquisition company Copley Acquisition Corp. in a deal valuing Ignite at a pro forma enterprise value of $150 million, the companies announced Thursday.
-
June 10, 2026
An Illinois federal judge on Wednesday refused to certify a class of former healthcare employees claiming that their wages were suppressed by alleged no-poach agreements among DaVita, UnitedHealth Group's Surgical Care Affiliates and Tenet Healthcare Corp. unit United Surgical Partners International, ruling that the proposed class is too diverse.